Form 4: Nautilus Biotechnology CFO Anna Mowry Granted Stock Options

Anna Mowry, CFO and Treasurer of Nautilus Biotechnology, received stock options for 160,000 shares on March 1, 2024.

Summary

• Anna Mowry, the CFO and Treasurer of Nautilus Biotechnology, Inc., was granted stock options on March 1, 2024.
• The stock options are for 160,000 shares of Nautilus Biotechnology's common stock.
• The exercise price of the options is $2.72 per share.
• The options vest over time, with 25% vesting on the one-year anniversary of January 1, 2024, and the remaining shares vesting monthly thereafter, subject to continuous service as a 'Service Provider'.
• The options expire on March 1, 2034.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral-positive signal.

Positives

• The grant of stock options to the CFO aligns her interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the CFO.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Nautilus Biotechnology.
• Comparable companies such as Pacific Biosciences, Twist Bioscience, and Quantum-Si also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance and retention.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the CFO to work towards increasing shareholder value.

Key Dates